These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35043731)

  • 1. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia.
    Ohana Z; Serraes S; Elder C; Katusa N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
    Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
    Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
    Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E
    J Hematol Oncol; 2023 May; 16(1):44. PubMed ID: 37131217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
    Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
    Wudhikarn K; King AC; Geyer MB; Roshal M; Bernal Y; Gyurkocza B; Perales MA; Park JH
    Blood Adv; 2022 Mar; 6(5):1432-1443. PubMed ID: 35042232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
    An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
    Moribe T; Xu L; Tajima K; Yonemoto N
    Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
    Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
    Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
    Cao HY; Wan CL; Xue SL
    Ann Hematol; 2023 Jan; 102(1):155-165. PubMed ID: 36394582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
    Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS
    Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
    Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
    Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
    Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antibody therapy for acute lymphoblastic leukemia].
    Hatta Y
    Rinsho Ketsueki; 2020; 61(8):922-928. PubMed ID: 32908056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.